Physician profile
Christopher N Thiessen
NPI 1306849914
$969.87
in general payments reported to CMS, 2019-2025
31 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $11.31 · 2021: $195 · 2022: $53.10 · 2023: $136 · 2024: $201 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $126.99 | 2023-2025 | Keveyis |
| Astrazeneca Pharmaceuticals LP | $114.37 | 2021-2025 | Airsupra, Breztri |
| Abbvie INC. | $61.05 | 2020-2025 | |
| Allergan, INC. | $60.68 | 2019 | |
| Astellas Pharma US INC | $59.25 | 2022-2025 | Veozah |
| Roche Diagnostics Corporation | $57.71 | 2019 | |
| Amgen INC. | $51.77 | 2023-2024 | Otezla, Repatha, Krystexxa |
| Kowa Pharmaceuticals America, INC. | $49.26 | 2021 | |
| Eisai INC. | $33.95 | 2021 | |
| Medtronic, INC. | $28.97 | 2023-2024 | Intellis Adaptivestim |
| Novartis Pharmaceuticals Corporation | $27.15 | 2021-2023 | |
| Pulmonx Corporation | $27.03 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Pfizer INC. | $26.49 | 2021 | |
| Collegium Pharmaceutical, INC. | $18.93 | 2025 | Belbuca |
| Bayer Healthcare Pharmaceuticals INC. | $16.97 | 2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.90 | 2025 | Caplyta |
| Baxter Healthcare | $16.16 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Neurocrine Biosciences, INC. | $15.78 | 2024 | Ingrezza |
| Cepheid | $15.25 | 2025 | Genexpert |
| Lilly USA, LLC | $14.99 | 2025 | Kisunla |
| Gilead Sciences, INC. | $13.47 | 2024 | |
| Myovant Sciences INC. | $13.16 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.92 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.58 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $12.05 | 2021 | |
| Nestle Healthcare Nutrition INC. | $12.01 | 2022 | |
| Grifols USA, LLC | $11.97 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.93 | 2021 | |
| Novo Nordisk INC | $11.78 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.46 | 2021 | |
| Phathom Pharmaceuticals, INC. | $6.89 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thiessen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.